Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ Diabetes mellitus requiring insulin · patients with Guillain‐Barré syndrome
Corticosteroid leads to higher adverse events ‐ diabetes mellitus requiring insulin compared with control (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to treatment discontinuation ( · adults and adolescents with pleural TB
The intervention may leads to higher adverse events leading to treatment discontinuation ( (low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
It is very uncertain whether ciclesonide changes adverse events Number of patients with adverse events compared with fluticasone (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Duration of trials: 12 to 20 weeks · adults and adolescents with persistent asthma
The intervention probably leads to higher serious adverse events Duration of trials: 12 to 20 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
1 finding from 1 review
Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review